CA
NZ
UK
AU
IND
US
Zivo Bioscience develops therapeutic and nutritional products derived from proprietary algal cultures, targeting animal health, human health and dietary-supplement markets. Its intellectual property centers on proprietary algal strains and patented production techniques. A notable structural development came in May 2026, when the company transitioned …
Atossa Therapeutics is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on breast cancer. Its lead asset is (Z)-endoxifen, an oral selective estrogen receptor modulator and degrader in Phase 2 development for breast-cancer treatment and risk reduction, with exploration in additional therapeutic areas. Through 2026 the …
BNB Plus Corp. is the rebranded successor to Applied DNA Sciences, a change unveiled in late 2025 as management pivoted toward a digital-asset treasury model centred on the BNB token. Crucially, the company did not abandon its scientific roots: it retains a biopharmaceutical and …
Trinity Biotech, headquartered in Ireland and listed on Nasdaq, develops and markets medical diagnostic products spanning clinical-laboratory and point-of-care testing, including assays for infectious diseases, sexually transmitted infections and diabetes monitoring. In a striking diversification, the company has launched Trinovium, a subsidiary focused on …
Nano-X Imaging develops digital X-ray and medical-imaging technology, most notably the Nanox.ARC, a multi-source tomosynthesis system built around its cold-cathode digital X-ray source, along with AI-based image-analysis applications and a teleradiology arm. Through 2026 the company has focused on commercialising that hardware and software. …
Accendra Health began trading on the New York Stock Exchange under the ticker ACH on January 2, 2026, after its predecessor, Owens & Minor, sold its Products & Healthcare Services distributionBusinessand the Owens & MinorBrandon December 31, 2025. What remained, the home-based care operation …
Reviva is a clinical-stage pharmaceutical company focused on brilaroxazine, an investigational treatment for schizophrenia and other central-nervous-system and inflammatory conditions. A notable structural development came on May 14, 2026, when Reviva's common stock moved from the Nasdaq Capital Market to the OTCQB Venture Market, …
Few sub-penny tickers carry as much historical baggage as Creative Edge Nutrition, Inc. (OTC:FITX). The company became a fixture of the 2013-2014 speculative cannabis frenzy, and more than a decade later the stock trades at essentially nothing on the over-the-counter market. The company today …
A new name, a controversial drug and a regulatory hold make Filana Therapeutics, Inc (NASDAQ: FLNA) one of the more closely watched reinventions in small-cap biotech. Investors who remember the ticker under its former identity will recognise the asset at the centre of the …
Few tickers illustrate the outer limits of micro-cap trading quite like Forza Innovations Inc (OTC:FORZ), a Wyoming-incorporated, shell-scale company whose shares change hands at a small fraction of a cent. With the stock effectively flat in the last closing session and priced near the …
Please wait processing your request...